$TPST · Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer.
More about this company
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Not currently held by tracked 13F filers — this page aggregates activist, insider, politician and research activity.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-04-02 | SCHEDULE 13D/A | Versant Venture Capital VI, L.P. | 1.1% | Low | filing |
| 2026-03-25 | SCHEDULE 13D/A | Angel Matthew | 37.4% | Med | filing |
| 2026-02-10 | SCHEDULE 13D | Angel Matthew | 35.9% | Med | filing |
| Filed | Insider | Role | Shares | Value | |
|---|
| 2026-03-25 | Angel Matthew | director+officer+10%-owner | 231,482 | $500,001 | Form 4 |